Related Experiment Videos
Triglyceride as a risk factor for coronary artery disease
1Cornell University Medical College, New York, New York, USA.
Insights
Triglyceride levels are linked to coronary artery disease (CAD) risk, especially when combined with high LDL cholesterol and low HDL cholesterol. Managing hypertriglyceridemia involves lifestyle changes and medications to reduce CAD risk.
Area of Science:
- Cardiology
- Lipid Metabolism
- Preventive Medicine
Background:
- The independent association between triglyceride levels and coronary artery disease (CAD) risk is less clear than that of LDL and HDL cholesterol.
- Triglycerides may act as a synergistic risk factor, particularly in the 'lipid triad' (high LDL, low HDL, high triglycerides).
- Heterogeneity of triglyceride-rich lipoproteins complicates their direct correlation with CAD risk.
Purpose of the Study:
- To evaluate the role of triglyceride concentrations in coronary artery disease (CAD) risk.
- To discuss the assessment and management of hypertriglyceridemia in the context of CAD.
- To explore the effectiveness of various lipid-lowering therapies.
Main Methods:
- Analysis of existing data on triglyceride concentrations and CAD risk.
- Review of evidence for triglycerides as independent and synergistic risk factors.
- Assessment of current methods for evaluating hypertriglyceridemia.
- Discussion of nonpharmacologic and pharmacologic management strategies.
Main Results:
- Triglyceride's independent role in CAD risk is debated, but it's a significant synergistic factor.
- The 'lipid triad' is associated with substantial risk reduction from lipid-lowering therapy.
- Fasting triglyceride levels and combined lipid profiles are practical assessment tools.
- Pharmacologic options like fibrates, niacin, and statins offer therapeutic benefits.
Conclusions:
- Hypertriglyceridemia is an important consideration in assessing global CAD risk.
- Management should prioritize lifestyle modifications, with pharmacologic interventions as needed.
- Combination therapy may be necessary for optimal lipid management in high-risk patients.
Abstract:
The data for an independent association between triglyceride concentrations and risk for coronary artery disease (CAD) are equivocal, unlike the data for low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol, which show strong, consistent, and opposing correlations with CAD risk. There is some evidence for triglyceride as an independent risk factor in certain subgroups, for example, women 50-69 years of age (Framingham Heart Study) and in patients with noninsulin-dependent diabetes. However, the evidence is stronger for triglyceride as a synergistic CAD risk factor. For example, patients with the "lipid triad" of high LDL cholesterol, low HDL cholesterol, and high triglyceride accounted for most of the event reduction with lipid-lowering therapy in the Helsinki Heart Study. An important confounder of the correlation between triglyceride and CAD risk is the heterogeneity of triglyceride-rich lipoproteins: the larger triglyceride-rich particles are thought not to be associated with CAD risk, whereas the smaller (and denser) particles are believed to be atherogenic. At present, measurement of fasting triglyceride levels and triglyceride assessment in conjunction with LDL cholesterol and HDL cholesterol concentrations are the most practical methods of evaluating hypertriglyceridemia in CAD risk, although postprandial lipemia may prove a better indicator of atherogenicity. Management of hypertriglyceridemia should initially focus on nonpharmacologic therapy (i.e., diet, exercise, weight control, and alcohol reduction). In diabetic patients, meticulous glycemic control is also important. However, if this approach proves inadequate, there are several pharmacologic options. Fibrates may be effective in decreasing triglyceride and increasing HDL cholesterol. Nicotinic acid (niacin) has been shown to decrease triglyceride, increase HDL cholesterol, lower LDL cholesterol, and decrease lipoprotein(a); it also decreases fibrinogen. The statins appear to be effective in decreasing triglyceride and LDL cholesterol in hypertriglyceridemia; however, they do not normalize metabolism of apolipoprotein B, and HDL cholesterol may remain low. Therefore, combination with a fibrate or niacin may be appropriate. Attention to hypertriglyceridemia with respect to increased CAD risk represents an important step in assessing global risk for CAD development.